Authority Magazine interviewed bit.bio's SVP of tech ops and manufacturing Kathryn Golden to discover her path to leadership and what she's learnt.
16.10.2023
Navigating the future of cell therapies with exec Kathryn Corzo
Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.
Synthego and bit.bio expand strategic partnership
Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...
We have achieved the Gold award from Green Impact
bit.bio received a gold award for its participation in the Green Impact awards for sustainability.
BlueRock Therapeutics and bit.bio announce collaboration
BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...
The "Brother Wright flight" of human health: Where can synbio take us?
In this episode of the SynBioBeta podcast, bit.bio CEO Mark Kotter discusses the influence synthetic biology is having on the futu...
Foundational US patent secured for bit.bio's opti-ox technology
bit.bio secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...
Endpoints 20 women biopharma leaders - bit.bio's Kathryn Corzo named
bit.bio's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.
.png)
The UK has the chance to lead the way in synbio. We must grasp it.
An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.